A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
Study sponsor: Phathom Pharmaceuticals, Inc. · PHAT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-10-20Estimated
Enrollment · participants500Estimated
Source updated2026-11-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.